Overview and Background
ACTD (ASEAN Common Technical Dossier)is a common technical document format used for drug marketing authorization applications in ASEAN countries.
In other words, it is a standardized format used for submitting drug registration applications for human use in ASEAN member countries.
In other regions, such as the Americas, Europe, and Japan, a similar format is known as the CTD (Common Technical Document) by ICH; ACTD is adapted to meet the regulatory requirements of ASEAN.
Within ASEAN, a pharmaceutical regulatory harmonization initiative is underway, and as part of this effort, the ACTD began its introduction in member states around January 2009.
Accordingly, related guidelines such as long-term stability testing requirements, process validation, and bioequivalence (BA/BE) testing guidelines have also been harmonized. Consequently, ASEAN member states (e.g., Indonesia, Malaysia, Singapore, Thailand, Vietnam) began requiring the submission of documents in ACTD format when applying for drug registration.
Its primary objective is to simplify the assessment process and reduce the administrative burden on applicants by unifying previously disparate requirements across countries. This is expected to enhance examination efficiency and reduce duplication of effort.
Additionally, one of the long-term goals is to pave the way for electronic submissions (eCTD) to streamline future administrative processes.
Key Requirements and Structure
ACTD is a guide that defines the structure of submission documents (dossier) and generally consists of4 bagian utama (Part I–IV).
Isi tiap bagian dirangkum sebagai berikut.
Part I: Administrative Information and Products
This section includes administrative documents which form the core of the submission.
Including the application form, applicant information, product summary (name, dosage form, composition), leaflet/instructions for use, list of manufacturers, and legal documents such as declarations and power of attorney, as required by local authorities.
The required documentation must comply with the respective national pharmaceutical regulations. Therefore, the ACTD only provides a template format; specific requirements may differ between countries.
Part II: Quality (Chemical, Pharmaceutical)
Loading data pertaining to the quality of active ingredients and formulations.
For example: active pharmaceutical ingredient (API) name, structure, manufacturing process, impurity profile, drug product formulation, manufacturing method, test specifications, stability test results — the complete Chemistry, Manufacturing and Controls (CMC) data.
Part II is mandatory for both innovator and generic products, and its structure is elaborated in detail (summary, list of documents, detailed data, and references).
Part III: Non-Clinical (Safety)
It contains preclinical study results, such as animal studies and in vitro tests, that support the product's safety profile.
It encompasses basic pharmacological data (pharmacodynamic studies), ADME studies, and toxicology studies (single-dose toxicity, repeated-dose toxicity, genotoxicity, reproductive toxicity, and carcinogenicity studies, if required).
This section is equivalent to Module 4 of the ICH-CTD and constitutes a critical component presenting scientific evidence to support product safety and efficacy.
Part IV: Clinical (Efficacy)
Loading human clinical trial data.
Including clinical pharmacology studies (PK/PD studies), Phase I–III clinical trial results and integrated reports, literature evidence, and post-marketing data, if available.
This section corresponds to Module 5 of the ICH-CTD and summarizes the clinical data demonstrating the efficacy and safety of the proposed drug, including individual case listings from clinical trials and detailed statistical analysis results.
The above presents the fundamental structure of the ACTD. Each section requires specific details to be provided by the applicant during document preparation.
Perlu digarisbawahi bahwa ACTD berfungsi sebagai A framework to standardize the structure of submission documents, while detailed technical guidelines regarding the content of each section are regulated by ICH guidelines or the national regulations of each country. For example, stability test requirements follow the ASEAN Stability Guidelines, while clinical trial requirements refer to the ICH (Efficacy) guideline series.
Thus, the ACTD provides a format for structuring and presenting submission documents, rather than defining the product's evaluation criteria. Applicants must complete the ACTD framework with comprehensive and relevant data to satisfy regulatory authority requirements.
Benefits and Objectives of Certification (Implementation)
The primary objective of ACTD implementation is to enhance the efficiency and streamlining of the drug marketing authorization assessment process.
Previously, each ASEAN member state employed distinct submission formats, often necessitating companies to duplicate documentation for every country and increasing administrative overhead. The introduction of the harmonized ACTD format enables companies to minimize redundant efforts and expedite time-to-market, consequently allowing patients across the ASEAN region faster access to novel therapies.
For regulatory authorities, format uniformity streamlines the review process and can shorten assessment timelines. Additionally, inter-authority collaboration during ACTD preparation strengthens information exchange and technical cooperation (e.g., GMP inspections and post-marketing surveillance).
Overall, ACTD helps lower approval acquisition costs and improve the success rate of transnational submissions, while simultaneously fostering enhanced documentation quality and the company's submission capabilities.
It should be noted that the ACTD serves as a framework guideline, not as a fully binding legal rule in every country. Some additional requirements may still apply nationally; therefore, applicants must adapt their documents according to local regulations.
Nevertheless, the initiative to adopt a common format by regulatory authorities and the industry provides a crucial foundation for the harmonization of pharmaceutical regulations in ASEAN. For companies, preparing documents in the ACTD format enables submission to multiple countries with minimal adjustments, thereby reducing submission costs and increasing the likelihood of approval.
Impact of Certification on Products, Services, and Consumers
The benefits of ACTD are primarily seen in the internal processes for pharmaceutical companies and regulators, but the ultimate effect is felt bypatient and consumerBy accelerating and simplifying the assessment process, ACTD helps accelerate the availability of new and generic drugs in the ASEAN market.
For instance, when an innovative drug is developed, varying submission formats across countries can lead to approval delays in some nations; the implementation of ACTD helps standardize these formats and narrow the gap in approval timelines between countries.
Consequently, patients in ASEAN will gain faster access to novel therapies, thereby contributing to more equitable treatment opportunities across the region.
Furthermore, clearer and more comprehensive submission documents tend to indirectly enhance the quality and safety of medicines. During the process of data restructuring, companies often identify and rectify deficiencies or inconsistencies.
Consequently, the submitted documents become more reliable, and inspections can be conducted with greater precision. This ensures that products on the market have undergone more thorough evaluation and verification, thereby providing consumers with a greater sense of security.
Furthermore, ACTD paves the way for the introduction of electronic Common Technical Document (eCTD) in the ASEAN region. With eCTD, the risk of errors or loss of physical documents is reduced, and interactions between authorities and applicants become more efficient.
This enables more rapid feedback on inspection results, streamlines the supply of medications to the market, and assists patients in obtaining essential medications promptly.
Overall, while ACTD operates behind the scenes for consumers, its impact is evident in enhanced access to new medications and increased confidence in the quality of marketed pharmaceuticals.
International Organizations and Related Regulatory Authorities
The ACTD was formulated within the ASEAN (Association of Southeast Asian Nations) framework through collaboration within the ASEAN Working Group on Pharmaceutical Regulatory Harmonization. Representatives of regulatory authorities from member states—including Indonesia, Malaysia, the Philippines, Singapore, Thailand, Brunei, Vietnam, Laos, Myanmar, and Cambodia—were involved in the development of these guidelines.
As an official ASEAN document, the ACTD guidelines have been adopted and are implemented as part of the pharmaceutical regulatory framework in several member states. For instance, authorities such as NPRA (Malaysia), FDA (Thailand), and BPOM (Indonesia) have issued provisions encouraging the use of ACTD-compliant formats in specific registration processes.
From an international perspective, the ACTD demonstrates strong alignment with the ICH CTD (International Council for Harmonisation — Common Technical Document). ICH is a forum for harmonizing drug regulations, involving stakeholders from Japan, the United States, and Europe; its output, the CTD, is now widely referenced across numerous jurisdictions.
The ACTD is based on the principles of the CTD but is adapted to the ASEAN regional context. Consequently, it exhibits significant alignment with the practices and requirements of authorities such as ICH, the EU, and US authorities (e.g., FDA). This makes documents prepared for the ASEAN market relatively easy to adapt for submission outside the region.
In addition, ACTR (ASEAN Common Technical Requirements)—a set of technical guidelines detailing content and standards for specific aspects such as stability testing and BA/BE studies—was also developed to complement ACTD. National authorities typically refer to ACTD and ACTR in conjunction during assessments, with the aim of reducing variations in interpretation among countries.
Essentially, although ACTD is a regional initiative, it leverages international knowledge (e.g., ICH, WHO) and promotes information exchange among regulatory authorities. This makes ACTD a successful example of region-led regulatory harmonization.